Tombolofish personal page - To The Moon

Tombolofish

Tombolofish

No personal profile

274Follow

9Followers

0Topic

0Badge

2022-05-17

Finally back to EV turn to go up and up

Sorry, the original content has been removed

2022-05-17

Keep the momentum going!

Hot Chinese ADRs Took Off in Morning Trading, with Pinduoduo Surging Over 11% and Alibaba Surging Nearly 9%

2022-05-04

Ok

Sorry, the original content has been removed

2022-05-04

Ok

Sorry, the original content has been removed

2022-04-18

Ok

Tesla Bear Michael Burry Defends SEC After Elon Musk's Rebuke

2022-02-15

Yes

Sorry, the original content has been removed

2022-02-08

Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits

Velodyne Lidar Shares Surged 25% in Morning Trading

2022-02-04

Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins

Snap Jumped Over 55% in Premarket Trading after Achieving Positive Free Cash Flow for the Year an Important Milestone

2022-01-04

Ok

Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake

2021-09-21

$Sea Ltd(SE)$ up and up

2021-09-18

Ok

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-09-18

$Zoom(ZM)$ Onwards to 300 dollars

2021-09-16

$Palantir Technologies Inc.(PLTR)$ Go up more

2021-09-11

$NASDAQ-100 Index ETF(QQQ)$ Go up more

2021-09-05

$Affirm Holdings, Inc.(AFRM)$ Prices cannot hold at 100 dollars, need management to update on how good the Amazon tie up before it can shoot up again

2021-09-04

$GS Acquisition Holdings Corp(GSAH)$ Faster go up please

2021-09-04

$Liquidia Technologies Inc(LQDA)$ When can pass 3 dollars

2021-09-03

$Palantir Technologies Inc.(PLTR)$ Heading to 30 dollars

2021-09-02

$MC Payment(TVV.SI)$ Pumping started, just exit in time before the dump begins

2021-08-31

Ok

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3563683901709118","uuid":"3563683901709118","gmtCreate":1600682287746,"gmtModify":1612965587786,"name":"Tombolofish","pinyin":"tombolofish","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":274,"tweetSize":53,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9029593286,"gmtCreate":1652796037445,"gmtModify":1676535162923,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Finally back to EV turn to go up and up&nbsp;","listText":"Finally back to EV turn to go up and up&nbsp;","text":"Finally back to EV turn to go up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9029593286","repostId":"1127355155","repostType":4,"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9029593154,"gmtCreate":1652796010078,"gmtModify":1676535162915,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Keep the momentum going!&nbsp;","listText":"Keep the momentum going!&nbsp;","text":"Keep the momentum going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9029593154","repostId":"1165575750","repostType":4,"repost":{"id":"1165575750","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652794621,"share":"https://ttm.financial/m/news/1165575750?lang=&edition=fundamental","pubTime":"2022-05-17 21:37","market":"us","language":"en","title":"Hot Chinese ADRs Took Off in Morning Trading, with Pinduoduo Surging Over 11% and Alibaba Surging Nearly 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165575750","media":"Tiger Newspress","summary":"Hot Chinese ADRs took off in morning trading, with Pinduoduo surging over 11% and Alibaba surging ne","content":"<html><head></head><body><p>Hot Chinese ADRs took off in morning trading, with Pinduoduo surging over 11% and Alibaba surging nearly 9%.<img src=\"https://static.tigerbbs.com/74f2f412c14efd6faa84a0c81877dde4\" tg-width=\"318\" tg-height=\"352\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Took Off in Morning Trading, with Pinduoduo Surging Over 11% and Alibaba Surging Nearly 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Took Off in Morning Trading, with Pinduoduo Surging Over 11% and Alibaba Surging Nearly 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-17 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Hot Chinese ADRs took off in morning trading, with Pinduoduo surging over 11% and Alibaba surging nearly 9%.<img src=\"https://static.tigerbbs.com/74f2f412c14efd6faa84a0c81877dde4\" tg-width=\"318\" tg-height=\"352\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","BABA":"阿里巴巴"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165575750","content_text":"Hot Chinese ADRs took off in morning trading, with Pinduoduo surging over 11% and Alibaba surging nearly 9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061493087,"gmtCreate":1651659937852,"gmtModify":1676534943666,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061493087","repostId":"2232289860","repostType":4,"isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061499584,"gmtCreate":1651659895809,"gmtModify":1676534943682,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061499584","repostId":"2232029455","repostType":4,"isVote":1,"tweetType":1,"viewCount":482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081725043,"gmtCreate":1650283212210,"gmtModify":1676534685774,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081725043","repostId":"1147021559","repostType":4,"repost":{"id":"1147021559","kind":"news","pubTimestamp":1650283153,"share":"https://ttm.financial/m/news/1147021559?lang=&edition=fundamental","pubTime":"2022-04-18 19:59","market":"us","language":"en","title":"Tesla Bear Michael Burry Defends SEC After Elon Musk's Rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1147021559","media":"Benzinga","summary":"Tesla Inc bear and hedge fund manager Michael Burry on Sunday defended the U.S.Securities and Exchan","content":"<html><head></head><body><p><b>Tesla Inc</b> bear and hedge fund manager <b>Michael Burry</b> on Sunday defended the U.S.<b>Securities and Exchange Commission</b> and took a shot at billionaire entrepreneur <b>Elon</b> <b>Musk</b> for flouting the agency&#39;s rules.</p><p><b>What Happened:</b> The “Big Short” fame investor said in a now-deleted Tweet that the U.S. regulatory agency was “nothing but professional” and that, unlike Musk, he did not have “billions” to make his own rules “and would never” do that.</p><p>&#34;In defense of the SEC, and particularly the SF office, they were nothing but professional in my dealings with them. But I don&#39;t have billions, can&#39;t make my own rules, and would never,&#34; Burry wrote on the microblogging site.</p><p><img src=\"https://static.tigerbbs.com/49218b37351eb2c40d9ae370b81202db\" tg-width=\"859\" tg-height=\"902\" width=\"100%\" height=\"auto\"/>Burry also shared a link to a <b>Forbes</b> story in which Musk calls the SEC regulators “bastards” over its investigation into an infamous 2018 tweet &#34;funding secured.&#34;</p><p><b>Why It Matters:</b> Burry and Musk have taken shots at each other in the past. Musk had last year called Burry a “broken clock” after <b>The Scion Asset Management</b> investor ridiculed Tesla’s high valuation. Burry had then accused Musk of selling Tesla shares last year to benefit from its higher price and repay personal debts.</p><p>Earlier this month, Burry said on Twitter that Musk “buying enough shares to control Twitter would be good for America. Period.”</p><p><b>Price Action:</b> Tesla stock closed 3.6% lower at $985 a share on Thursday.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Bear Michael Burry Defends SEC After Elon Musk's Rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Bear Michael Burry Defends SEC After Elon Musk's Rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-18 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/government/22/04/26659492/tesla-bear-michael-burry-defends-sec-after-elon-musks-rebuke><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla Inc bear and hedge fund manager Michael Burry on Sunday defended the U.S.Securities and Exchange Commission and took a shot at billionaire entrepreneur Elon Musk for flouting the agency's rules....</p>\n\n<a href=\"https://www.benzinga.com/government/22/04/26659492/tesla-bear-michael-burry-defends-sec-after-elon-musks-rebuke\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/government/22/04/26659492/tesla-bear-michael-burry-defends-sec-after-elon-musks-rebuke","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147021559","content_text":"Tesla Inc bear and hedge fund manager Michael Burry on Sunday defended the U.S.Securities and Exchange Commission and took a shot at billionaire entrepreneur Elon Musk for flouting the agency's rules.What Happened: The “Big Short” fame investor said in a now-deleted Tweet that the U.S. regulatory agency was “nothing but professional” and that, unlike Musk, he did not have “billions” to make his own rules “and would never” do that.\"In defense of the SEC, and particularly the SF office, they were nothing but professional in my dealings with them. But I don't have billions, can't make my own rules, and would never,\" Burry wrote on the microblogging site.Burry also shared a link to a Forbes story in which Musk calls the SEC regulators “bastards” over its investigation into an infamous 2018 tweet \"funding secured.\"Why It Matters: Burry and Musk have taken shots at each other in the past. Musk had last year called Burry a “broken clock” after The Scion Asset Management investor ridiculed Tesla’s high valuation. Burry had then accused Musk of selling Tesla shares last year to benefit from its higher price and repay personal debts.Earlier this month, Burry said on Twitter that Musk “buying enough shares to control Twitter would be good for America. Period.”Price Action: Tesla stock closed 3.6% lower at $985 a share on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095241605,"gmtCreate":1644937007915,"gmtModify":1676533977369,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095241605","repostId":"2211863696","repostType":4,"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096160043,"gmtCreate":1644331478324,"gmtModify":1676533913439,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits&nbsp;","listText":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits&nbsp;","text":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096160043","repostId":"1112802067","repostType":4,"repost":{"id":"1112802067","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644330620,"share":"https://ttm.financial/m/news/1112802067?lang=&edition=fundamental","pubTime":"2022-02-08 22:30","market":"us","language":"en","title":"Velodyne Lidar Shares Surged 25% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1112802067","media":"Tiger Newspress","summary":"Velodyne Lidar shares surged 25% in morning trading as Amazon received a warrant to purchase up to 3","content":"<html><head></head><body><p>Velodyne Lidar shares surged 25% in morning trading as Amazon received a warrant to purchase up to 39.6M of the company&#39;s shares.<img src=\"https://static.tigerbbs.com/14daf19257112ed414b799f52aae04ab\" tg-width=\"827\" tg-height=\"636\" width=\"100%\" height=\"auto\"/>The vesting of the warrant shares is based on discretionary payments made by Amazon pursuant to existing commercial agreements between <a href=\"https://laohu8.com/S/VLDR\">Velodyne</a> and <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>, according to an 8-K filing. The warrant may be any time before Feb. 4, 2030 at an exercise price of $4.18 per share, which was determined based on the 30-day volume-weighted average price for the common stock as of Feb 3.</p><p>The warrant shares will vest over time based on discretionary payments to Velodyne by Amazon (whether made directly from Amazon, its affiliates or by a third party on behalf of Amazon) of up to $200M, according to the filing.</p><p>The positive news from Amazon comes after the stock plunged almost 85% over the past year amid internal struggles at the company with the former CEO stepping down in July. The ousted founder of Velodyne in August called for the resignation of the sensor company&#39;s board chairman and a director.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Velodyne Lidar Shares Surged 25% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Velodyne Lidar Shares Surged 25% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-08 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Velodyne Lidar shares surged 25% in morning trading as Amazon received a warrant to purchase up to 39.6M of the company&#39;s shares.<img src=\"https://static.tigerbbs.com/14daf19257112ed414b799f52aae04ab\" tg-width=\"827\" tg-height=\"636\" width=\"100%\" height=\"auto\"/>The vesting of the warrant shares is based on discretionary payments made by Amazon pursuant to existing commercial agreements between <a href=\"https://laohu8.com/S/VLDR\">Velodyne</a> and <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>, according to an 8-K filing. The warrant may be any time before Feb. 4, 2030 at an exercise price of $4.18 per share, which was determined based on the 30-day volume-weighted average price for the common stock as of Feb 3.</p><p>The warrant shares will vest over time based on discretionary payments to Velodyne by Amazon (whether made directly from Amazon, its affiliates or by a third party on behalf of Amazon) of up to $200M, according to the filing.</p><p>The positive news from Amazon comes after the stock plunged almost 85% over the past year amid internal struggles at the company with the former CEO stepping down in July. The ousted founder of Velodyne in August called for the resignation of the sensor company&#39;s board chairman and a director.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VLDR":"威力登激光雷达"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112802067","content_text":"Velodyne Lidar shares surged 25% in morning trading as Amazon received a warrant to purchase up to 39.6M of the company's shares.The vesting of the warrant shares is based on discretionary payments made by Amazon pursuant to existing commercial agreements between Velodyne and Amazon, according to an 8-K filing. The warrant may be any time before Feb. 4, 2030 at an exercise price of $4.18 per share, which was determined based on the 30-day volume-weighted average price for the common stock as of Feb 3.The warrant shares will vest over time based on discretionary payments to Velodyne by Amazon (whether made directly from Amazon, its affiliates or by a third party on behalf of Amazon) of up to $200M, according to the filing.The positive news from Amazon comes after the stock plunged almost 85% over the past year amid internal struggles at the company with the former CEO stepping down in July. The ousted founder of Velodyne in August called for the resignation of the sensor company's board chairman and a director.","news_type":1},"isVote":1,"tweetType":1,"viewCount":849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098012264,"gmtCreate":1643968038368,"gmtModify":1676533877297,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","listText":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","text":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098012264","repostId":"1149790237","repostType":4,"repost":{"id":"1149790237","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643965582,"share":"https://ttm.financial/m/news/1149790237?lang=&edition=fundamental","pubTime":"2022-02-04 17:06","market":"us","language":"en","title":"Snap Jumped Over 55% in Premarket Trading after Achieving Positive Free Cash Flow for the Year an Important Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1149790237","media":"Tiger Newspress","summary":"Snap jumped over 55% in premarket trading after achieving positive free cash flow for the year an im","content":"<html><head></head><body><p>Snap jumped over 55% in premarket trading after achieving positive free cash flow for the year an important milestone.</p><p><img src=\"https://static.tigerbbs.com/3e3e0161d3e9e8dfac1d3ff05a014a03\" tg-width=\"769\" tg-height=\"565\" width=\"100%\" height=\"auto\"/>Snap reported quarterly revenue of $1.3 billion, which beat the $1.2 billion estimate. The company reported quarterly adjusted earnings of 22 cents per share, which more than doubled the estimate of 10 cents per share.</p><p>Global daily active users totaled 319 million in the fourth quarter, representing a 20% year-over-year increase. Snap highlighted that year-over-year growth in DAUs has been 20% or more for five consecutive quarters now.</p><p>Average revenue per user reached $4.06 during the quarter, up from $3.44 in the fourth quarter of 2020.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Snap Jumped Over 55% in Premarket Trading after Achieving Positive Free Cash Flow for the Year an Important Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSnap Jumped Over 55% in Premarket Trading after Achieving Positive Free Cash Flow for the Year an Important Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-04 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Snap jumped over 55% in premarket trading after achieving positive free cash flow for the year an important milestone.</p><p><img src=\"https://static.tigerbbs.com/3e3e0161d3e9e8dfac1d3ff05a014a03\" tg-width=\"769\" tg-height=\"565\" width=\"100%\" height=\"auto\"/>Snap reported quarterly revenue of $1.3 billion, which beat the $1.2 billion estimate. The company reported quarterly adjusted earnings of 22 cents per share, which more than doubled the estimate of 10 cents per share.</p><p>Global daily active users totaled 319 million in the fourth quarter, representing a 20% year-over-year increase. Snap highlighted that year-over-year growth in DAUs has been 20% or more for five consecutive quarters now.</p><p>Average revenue per user reached $4.06 during the quarter, up from $3.44 in the fourth quarter of 2020.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149790237","content_text":"Snap jumped over 55% in premarket trading after achieving positive free cash flow for the year an important milestone.Snap reported quarterly revenue of $1.3 billion, which beat the $1.2 billion estimate. The company reported quarterly adjusted earnings of 22 cents per share, which more than doubled the estimate of 10 cents per share.Global daily active users totaled 319 million in the fourth quarter, representing a 20% year-over-year increase. Snap highlighted that year-over-year growth in DAUs has been 20% or more for five consecutive quarters now.Average revenue per user reached $4.06 during the quarter, up from $3.44 in the fourth quarter of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001454702,"gmtCreate":1641307771313,"gmtModify":1676533595873,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001454702","repostId":"1133481697","repostType":4,"repost":{"id":"1133481697","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641306703,"share":"https://ttm.financial/m/news/1133481697?lang=&edition=fundamental","pubTime":"2022-01-04 22:31","market":"us","language":"en","title":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1133481697","media":"Tiger Newspress","summary":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.Tencent said on Tuesd","content":"<html><head></head><body><p>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.<img src=\"https://static.tigerbbs.com/e06a3e8e4e168efe476a15ae1f3e5f99\" tg-width=\"760\" tg-height=\"561\" width=\"100%\" height=\"auto\"/>Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.</p><p>Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea&#39;s last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.</p><p>Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea tumbled nearly 8% in morning trading as Tencent would cut its voting stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-04 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.<img src=\"https://static.tigerbbs.com/e06a3e8e4e168efe476a15ae1f3e5f99\" tg-width=\"760\" tg-height=\"561\" width=\"100%\" height=\"auto\"/>Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.</p><p>Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea&#39;s last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.</p><p>Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133481697","content_text":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea's last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869300506,"gmtCreate":1632239865505,"gmtModify":1676530733070,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;up and up&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;up and up&nbsp;","text":"$Sea Ltd(SE)$ up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869300506","isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887392784,"gmtCreate":1631971325048,"gmtModify":1676530680302,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887392784","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887392839,"gmtCreate":1631971257721,"gmtModify":1676530680286,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>&nbsp;Onwards to 300 dollars","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>&nbsp;Onwards to 300 dollars","text":"$Zoom(ZM)$ Onwards to 300 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887392839","isVote":1,"tweetType":1,"viewCount":112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885540723,"gmtCreate":1631805433862,"gmtModify":1676530641762,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Go up more","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Go up more","text":"$Palantir Technologies Inc.(PLTR)$ Go up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885540723","isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881625423,"gmtCreate":1631333530962,"gmtModify":1676530531387,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QQQ\">$NASDAQ-100 Index ETF(QQQ)$</a>&nbsp;Go up more","listText":"<a href=\"https://laohu8.com/S/QQQ\">$NASDAQ-100 Index ETF(QQQ)$</a>&nbsp;Go up more","text":"$NASDAQ-100 Index ETF(QQQ)$ Go up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881625423","isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814887712,"gmtCreate":1630806369036,"gmtModify":1676530397140,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AFRM\">$Affirm Holdings, Inc.(AFRM)$</a>&nbsp;Prices cannot hold at 100 dollars, need management to update on how good the Amazon tie&nbsp; up before it can shoot up again&nbsp;","listText":"<a href=\"https://laohu8.com/S/AFRM\">$Affirm Holdings, Inc.(AFRM)$</a>&nbsp;Prices cannot hold at 100 dollars, need management to update on how good the Amazon tie&nbsp; up before it can shoot up again&nbsp;","text":"$Affirm Holdings, Inc.(AFRM)$ Prices cannot hold at 100 dollars, need management to update on how good the Amazon tie up before it can shoot up again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814887712","isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814966786,"gmtCreate":1630745238445,"gmtModify":1676530389433,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSAH\">$GS Acquisition Holdings Corp(GSAH)$</a>&nbsp;Faster go up please","listText":"<a href=\"https://laohu8.com/S/GSAH\">$GS Acquisition Holdings Corp(GSAH)$</a>&nbsp;Faster go up please","text":"$GS Acquisition Holdings Corp(GSAH)$ Faster go up please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814966786","isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814966617,"gmtCreate":1630745177339,"gmtModify":1676530389416,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LQDA\">$Liquidia Technologies Inc(LQDA)$</a>&nbsp;When can pass 3 dollars","listText":"<a href=\"https://laohu8.com/S/LQDA\">$Liquidia Technologies Inc(LQDA)$</a>&nbsp;When can pass 3 dollars","text":"$Liquidia Technologies Inc(LQDA)$ When can pass 3 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/814966617","isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815146004,"gmtCreate":1630660151808,"gmtModify":1676530368718,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Heading to 30 dollars","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Heading to 30 dollars","text":"$Palantir Technologies Inc.(PLTR)$ Heading to 30 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815146004","isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812900563,"gmtCreate":1630544148752,"gmtModify":1676530334960,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a>&nbsp;Pumping started, just exit in time before the dump begins&nbsp;","listText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a>&nbsp;Pumping started, just exit in time before the dump begins&nbsp;","text":"$MC Payment(TVV.SI)$ Pumping started, just exit in time before the dump begins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812900563","isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818276740,"gmtCreate":1630417288380,"gmtModify":1676530297691,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818276740","repostId":"1155360019","repostType":4,"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":118613083,"gmtCreate":1622730015942,"gmtModify":1704189994090,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;Buy in at too high a price ?","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;Buy in at too high a price ?","text":"$BlackBerry(BB)$ Buy in at too high a price ?","images":[{"img":"https://static.tigerbbs.com/fddcd46d3e4f422cab6078151475a8f0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/118613083","isVote":1,"tweetType":1,"viewCount":635,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575004925185220","authorId":"3575004925185220","name":"BIackTlger","avatar":"https://static.tigerbbs.com/1b6bbad3170909ed1e85e56dfb66d38e","crmLevel":9,"crmLevelSwitch":1,"idStr":"3575004925185220","authorIdStr":"3575004925185220"},"content":"Why to high? What is your belief and targeted selling price ?","text":"Why to high? What is your belief and targeted selling price ?","html":"Why to high? What is your belief and targeted selling price ?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9061493087,"gmtCreate":1651659937852,"gmtModify":1676534943666,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061493087","repostId":"2232289860","repostType":4,"repost":{"id":"2232289860","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1651659513,"share":"https://ttm.financial/m/news/2232289860?lang=&edition=fundamental","pubTime":"2022-05-04 18:18","market":"us","language":"en","title":"Elon Musk Floats Idea of \"Slight Cost\" for Commercial Twitter Users","url":"https://stock-news.laohu8.com/highlight/detail?id=2232289860","media":"Dow Jones","summary":"Elon Musk has floated the idea of introducing a fee for some users of Twitter once he completes his ","content":"<html><head></head><body><p>Elon Musk has floated the idea of introducing a fee for some users of <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> once he completes his $44 billion buyout of the social media platform.</p><p>&#34;Twitter will always be free for casual users, but maybe a slight cost for commercial/government users,&#34; Musk said in a tweet on Tuesday.</p><p>&#34;Some revenue is better than none!&#34; he added in another tweet.</p><p>The Tesla (ticker: TSLA) CEO has been dropping hints about how he might grow revenue at Twitter ever since his takeover offer of $54.20 a share for the social media company was approved by its board last month. These include cutting the price of the company&#39;s new premium subscription service, Twitter Blue.</p><p>Shares of Twitter (TWTR) were down 0.2% in premarket on Wednesday at $48.78, below Musk&#39;s offer price. The stock has risen 13.07% so far in 2022.</p><p>Earlier on Tuesday, Musk told potential investors that he could take Twitter public again in as little as three years, The Wall Street Journal reported, citing people familiar with the matter.</p><p>Musk has been talking to investors, including private-equity firms, to help reduce the $21 billion cash contribution he has committed to help finance the deal, the Journal has reported.</p><p>Musk&#39;s acquisition of Twitter is expected to close later this year, subject to conditions including the approval of Twitter shareholders and regulators.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk Floats Idea of \"Slight Cost\" for Commercial Twitter Users</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk Floats Idea of \"Slight Cost\" for Commercial Twitter Users\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-04 18:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Elon Musk has floated the idea of introducing a fee for some users of <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> once he completes his $44 billion buyout of the social media platform.</p><p>&#34;Twitter will always be free for casual users, but maybe a slight cost for commercial/government users,&#34; Musk said in a tweet on Tuesday.</p><p>&#34;Some revenue is better than none!&#34; he added in another tweet.</p><p>The Tesla (ticker: TSLA) CEO has been dropping hints about how he might grow revenue at Twitter ever since his takeover offer of $54.20 a share for the social media company was approved by its board last month. These include cutting the price of the company&#39;s new premium subscription service, Twitter Blue.</p><p>Shares of Twitter (TWTR) were down 0.2% in premarket on Wednesday at $48.78, below Musk&#39;s offer price. The stock has risen 13.07% so far in 2022.</p><p>Earlier on Tuesday, Musk told potential investors that he could take Twitter public again in as little as three years, The Wall Street Journal reported, citing people familiar with the matter.</p><p>Musk has been talking to investors, including private-equity firms, to help reduce the $21 billion cash contribution he has committed to help finance the deal, the Journal has reported.</p><p>Musk&#39;s acquisition of Twitter is expected to close later this year, subject to conditions including the approval of Twitter shareholders and regulators.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4099":"汽车制造商","BK4511":"特斯拉概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4574":"无人驾驶","TWTR":"Twitter","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4527":"明星科技股","BK4581":"高盛持仓","BK4555":"新能源车","BK4550":"红杉资本持仓","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2232289860","content_text":"Elon Musk has floated the idea of introducing a fee for some users of Twitter once he completes his $44 billion buyout of the social media platform.\"Twitter will always be free for casual users, but maybe a slight cost for commercial/government users,\" Musk said in a tweet on Tuesday.\"Some revenue is better than none!\" he added in another tweet.The Tesla (ticker: TSLA) CEO has been dropping hints about how he might grow revenue at Twitter ever since his takeover offer of $54.20 a share for the social media company was approved by its board last month. These include cutting the price of the company's new premium subscription service, Twitter Blue.Shares of Twitter (TWTR) were down 0.2% in premarket on Wednesday at $48.78, below Musk's offer price. The stock has risen 13.07% so far in 2022.Earlier on Tuesday, Musk told potential investors that he could take Twitter public again in as little as three years, The Wall Street Journal reported, citing people familiar with the matter.Musk has been talking to investors, including private-equity firms, to help reduce the $21 billion cash contribution he has committed to help finance the deal, the Journal has reported.Musk's acquisition of Twitter is expected to close later this year, subject to conditions including the approval of Twitter shareholders and regulators.","news_type":1},"isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095241605,"gmtCreate":1644937007915,"gmtModify":1676533977369,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095241605","repostId":"2211863696","repostType":4,"repost":{"id":"2211863696","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1644936189,"share":"https://ttm.financial/m/news/2211863696?lang=&edition=fundamental","pubTime":"2022-02-15 22:43","market":"us","language":"en","title":"GM Extends EV Bolt Production Halt but Plans to Soon Resume Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2211863696","media":"Reuters","summary":"WASHINGTON, Feb 15 (Reuters) - General Motors Co    said Tuesday it is extending a production halt t","content":"<html><head></head><body><p>WASHINGTON, Feb 15 (Reuters) - General Motors Co    said Tuesday it is extending a production halt to its Chevrolet Bolt electric vehicle until early April but plans to soon resume retail sales.</p><p>The largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires and halted production and retail sales. In December, GM extended its production shutdown through the end of February. GM said Tuesday it plans to resume production of the Bolt at a Michigan plant the week of April 4.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GM Extends EV Bolt Production Halt but Plans to Soon Resume Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGM Extends EV Bolt Production Halt but Plans to Soon Resume Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-02-15 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>WASHINGTON, Feb 15 (Reuters) - General Motors Co    said Tuesday it is extending a production halt to its Chevrolet Bolt electric vehicle until early April but plans to soon resume retail sales.</p><p>The largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires and halted production and retail sales. In December, GM extended its production shutdown through the end of February. GM said Tuesday it plans to resume production of the Bolt at a Michigan plant the week of April 4.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211863696","content_text":"WASHINGTON, Feb 15 (Reuters) - General Motors Co    said Tuesday it is extending a production halt to its Chevrolet Bolt electric vehicle until early April but plans to soon resume retail sales.The largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires and halted production and retail sales. In December, GM extended its production shutdown through the end of February. GM said Tuesday it plans to resume production of the Bolt at a Michigan plant the week of April 4.","news_type":1},"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813557665,"gmtCreate":1630218932657,"gmtModify":1676530246228,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;Faster back to 900","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;Faster back to 900","text":"$Tesla Motors(TSLA)$ Faster back to 900","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/813557665","isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818276740,"gmtCreate":1630417288380,"gmtModify":1676530297691,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818276740","repostId":"1155360019","repostType":4,"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835937277,"gmtCreate":1629683696899,"gmtModify":1676530097133,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a>&nbsp;Is it pump and dump?&nbsp;","listText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a>&nbsp;Is it pump and dump?&nbsp;","text":"$MC Payment(TVV.SI)$ Is it pump and dump?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835937277","isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"content":"Bid up the price higher and higher to lure buyers in, then one shot sell all, and the price collapse","text":"Bid up the price higher and higher to lure buyers in, then one shot sell all, and the price collapse","html":"Bid up the price higher and higher to lure buyers in, then one shot sell all, and the price collapse"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887392784,"gmtCreate":1631971325048,"gmtModify":1676530680302,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887392784","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096160043,"gmtCreate":1644331478324,"gmtModify":1676533913439,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits&nbsp;","listText":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits&nbsp;","text":"Yesterday post market surge 60%, today pre market only surge 25%, means it actually drop more than 30%. Shorting it will gain quick profits","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096160043","repostId":"1112802067","repostType":4,"isVote":1,"tweetType":1,"viewCount":849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001454702,"gmtCreate":1641307771313,"gmtModify":1676533595873,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001454702","repostId":"1133481697","repostType":4,"repost":{"id":"1133481697","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641306703,"share":"https://ttm.financial/m/news/1133481697?lang=&edition=fundamental","pubTime":"2022-01-04 22:31","market":"us","language":"en","title":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1133481697","media":"Tiger Newspress","summary":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.Tencent said on Tuesd","content":"<html><head></head><body><p>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.<img src=\"https://static.tigerbbs.com/e06a3e8e4e168efe476a15ae1f3e5f99\" tg-width=\"760\" tg-height=\"561\" width=\"100%\" height=\"auto\"/>Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.</p><p>Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea&#39;s last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.</p><p>Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea tumbled nearly 8% in morning trading as Tencent would cut its voting stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-04 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.<img src=\"https://static.tigerbbs.com/e06a3e8e4e168efe476a15ae1f3e5f99\" tg-width=\"760\" tg-height=\"561\" width=\"100%\" height=\"auto\"/>Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.</p><p>Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea&#39;s last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.</p><p>Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133481697","content_text":"Sea tumbled nearly 8% in morning trading as Tencent would cut its voting stake.Tencent said on Tuesday it would cut its stake in Sea Ltd, reducing its voting power to under 10%.Tencent is selling at a price range of $208.00-$212.00 per share, bringing the total divestment to up to $3.1 billion. Sea's last close price was $223.31 per share. The trade has not been priced, according to a person with direct knowledge.Tencent will divest about 14.5 million shares, reducing its stake to 18.7% from 21.3%. The company said it intends to retain the substantial majority of its stake in Sea for the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098012264,"gmtCreate":1643968038368,"gmtModify":1676533877297,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","listText":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","text":"Short it for quick profit. The jump is reduced from 55% to 45% in just 30 mins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098012264","repostId":"1149790237","repostType":4,"isVote":1,"tweetType":1,"viewCount":670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869300506,"gmtCreate":1632239865505,"gmtModify":1676530733070,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;up and up&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;up and up&nbsp;","text":"$Sea Ltd(SE)$ up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869300506","isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885540723,"gmtCreate":1631805433862,"gmtModify":1676530641762,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Go up more","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Go up more","text":"$Palantir Technologies Inc.(PLTR)$ Go up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885540723","isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815146004,"gmtCreate":1630660151808,"gmtModify":1676530368718,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Heading to 30 dollars","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>&nbsp;Heading to 30 dollars","text":"$Palantir Technologies Inc.(PLTR)$ Heading to 30 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815146004","isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134120148,"gmtCreate":1622211855584,"gmtModify":1704181637819,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/134120148","repostId":"1170226387","repostType":4,"repost":{"id":"1170226387","kind":"news","pubTimestamp":1622211688,"share":"https://ttm.financial/m/news/1170226387?lang=&edition=fundamental","pubTime":"2021-05-28 22:21","market":"fut","language":"en","title":"Headed for the Moon? Make Sure You Avoid These 4 Big Cryptocurrency Scams","url":"https://stock-news.laohu8.com/highlight/detail?id=1170226387","media":"investorplace","summary":"Cryptocurrencies are amazing. They allow us to send lightning-fast transactions overseas, develop applications in a decentralized way, encrypt information in a manner that is safe and effective, and — most importantly — they give us an innovative new way to grow our wealth.Bitcoin blazed the trail, creating the first generation of crypto billionaires and blockchain entrepreneurs. In its wake, altcoins have been cropping up everywhere as potential gateways to gains. Although this crypto craze bri","content":"<p>Cryptocurrencies are amazing. They allow us to send lightning-fast transactions overseas, develop applications in a decentralized way, encrypt information in a manner that is safe and effective, and — most importantly — they give us an innovative new way to grow our wealth.<b>Bitcoin</b>(CCC:<b>BTC-USD</b>) blazed the trail, creating the first generation of crypto billionaires and blockchain entrepreneurs. In its wake, altcoins have been cropping up everywhere as potential gateways to gains. Although this crypto craze brings great opportunity, it also brings a wealth of cryptocurrency scams, like theElon Musk impersonators who’ve made off with millionsin coins.</p><p>This new frontier of digital, decentralized finance can be a labyrinth for new investors. There are many bad actors who know that, and seek to take advantage of those who are just beginning to explore the complex world of cryptocurrencies.</p><p>At<i>InvestorPlace</i>, we want to ensure our readers are as educated as possible in order to tell the real from the fake. In the world of traditional investing, this means highlighting the risks that come with penny stocks and other volatile names. In the world of cryptocurrencies, it’s the same.</p><p>And, just like with traditional pump-and-dump schemes and other stock scams, there are signs you can look for to avoid falling for fraud.</p><p>Altcoin schemes are frustrating because they can take many forms.AARPsays it best, though: “For all cryptocurrency’s high-tech gloss, many of the related scams are just newfangled versions of classic frauds.”</p><p>In the six months from October 2020 to May 2021, those Elon Musk impersonators have been making a killing. By just creating a Twitter account using Musk’s profile image and name, these scammers have convinced users to send over $2 million in Bitcoin to them. The scam, a play on the popular“Nigerian prince”email scheme, is shockingly lucrative. And, unfortunately, it’s only a drop in the bucket as far as crypto scams go.</p><p>With this in mind, it’s a good idea to make yourself familiar with different crypto schemes to minimize the risk of falling victim to one. Let’s take a look at some of the most common crypto scams.</p><p><b>Cryptocurrency Scams to Avoid: Fake ICOs</b></p><p>A fake ICO, or initial coin offering, takes a similar shape to a pre-IPO scam. In it, a cryptocurrency will pop up. It will have a white paper and all the fixings, advertising a “groundbreaking” new blockchain tech oryield-farming modelthat is certain to bring<i>huge gains</i>.</p><p>These crypto scams usually also have great marketing. Victims are the type who are prone to speculative investing; they’ll bite, pouring money into an initial offering in order to get those “big gains.” Before you know it, they’re seeing no movement in their portfolio. Or, they’re getting a worthless token with absolutely no utility. The scammer rides off into the sunset with a full wallet.</p><p>A famous example of a fake ICO is&nbsp;<b>Pincoin</b>. The development teamraised $660 million from investors, launched a different coin from the one advertised, and compensated the victims with loads of the worthless crypto before disappearing. The resulting protests outside their Ho Chi Minh City office were a fruitless effort; the seven developersemptied the commercial space and never came back.</p><p>So how do you avoid these cryptocurrency scams? The key for spotting a fake ICO is in the details.</p><p>This means you should pore over the white paper, which is the cornerstone document to a blockchain project. It contains all the details of how a crypto functions, how it is used, and the roadmap for the underlying company and team.</p><p>The details of a white paper are where you will find the evidence of a scam. If it doesn’t have a white paper, that’s an immediate red flag. If there are typos, or if there is a lack of a clear vision or roadmap for the crypto, these are all signs of a cryptocurrency scam.</p><p><b>Ponzi Schemes</b></p><p>If you’re at all familiar with investing, you are familiar with Ponzi schemes. The scam is one in which old investors are paid with the money of new investors, under the guise of receiving gains from their investment. It’s a scheme as old as — well, as old as Charles Ponzi, who originated the scam under the façade of selling discounted postage stamps.</p><p>In the 100-plus years since, the scam has remained, but it’s become more sophisticated.</p><p>With cryptos, a Ponzi scheme takes a similar form. Scammers offer huge gains through an “up and coming” new arbitrage model. Money is taken from the new investors, given to the old investors disguised as the gains, and the scammer pockets his share.</p><p>The most notable Ponzi scheme in crypto is<b>Bitconnect</b>, a high-yield investment program disguised as an open-source currency. Users could stake their coins for high daily interest, which was actually just money taken from newer investors. And the company made a huge profit; Bitconnectwas a top 20 cryptocurrencyin terms of market capitalization before its collapse.</p><p>The U.S. Securities and Exchange Commissionkeeps a handy guideon spotting this particular crypto scheme. Investors should look out for the classic “high return, no risk” promise typical of a cryptocurrency scam. Overly complex strategies and returns that look uncannily consistent are also signs of fraud. Because of the nature of cryptos, overly consistent returns are unusual. Things ebb and flow on the market, so when returns are the same month after month, it suggests the gains are artificial.</p><p><b>Cryptocurrency Scams to Avoid: Fraud Wallets</b></p><p>A fraud wallet scam is closely related to the internet-age-old practice of phishing. But rather than sending out emails pretending to be a reputable company, fraud wallets typically wait for you to come to them.</p><p>Fraud wallets can take the shape of a website or a mobile app, just like a real crypto wallet. Everything might seem totally legitimate: a shiny logo, high ratings, a sleek interface; heck, just the fact that a wallet app is on the Apple App Store could seem like reason enough to believe a wallet is real.</p><p>Much like a lemon car, the fraud takes advantage of the adage “looks can be deceiving.” When one signs up for a fraudulent wallet, they do all the work for the scammer. They add in their information, link a card or two, and load crypto right into the scammers’ hands. Then, just as quickly as the scammers showed up, they vanish with the coins.</p><p><b>Trezor’s doppelgänger app</b>&nbsp;is a famous example of a fraud wallet scheme, evengetting coverage in the<i>Washington Post</i>. The app posed as Trezor, which is a reputable crypto wallet. However, the doppelgänger app was acting in bad faith and stripped customers’ coins. As a result, victims have lost nearly $1 million in cryptocurrency. The most disturbing part of it all is that the app was housed on Apple’s platform, a supposedly safe space to download applications. It proves that you can’t let your guard down.</p><p>My advice here is to stick with the biggest wallet players. Look for wallets with blue checkmarks on their Twitter profiles. Go to websites through official links to be sure you’re on legitimate sites. Don’t necessarily trust an app just because it has hundreds of reviews on an app store; security firm ESET says to “only trust cryptocurrency-related and other finance apps if they are linked from the official website of the service.”</p><p>Double and triple check that you’re looking through official channels when preparing to sign up for a wallet in-browser. If you go through as many channels as possible that evaluate content for fraud, the likelihood that you are using a crypto scam product decreases significantly.</p><p><b>Social Media Scams</b></p><p>Social media scams are not exclusive to cryptocurrency. They’ve been around as long as social media has existed, and while all seek different ends, many recent social media scams want your digital currency.</p><p>Another variant of phishing, social media scams typically involve an account advertising big gains, a survey, or something similar, with a link. Clicking the link can lead to malware being installed on one’s device. Or, scammers can simply lure you into entering your information.</p><p>In the crypto-sphere, these scams usually target Bitcoin holders, due simply to the coin’s high value and rapid growth. A famous scam occurred in 2020, when hackers gained access to a slew of different celebrities’ Twitter accounts. Tweets went out from Barack Obama, Elon Musk and Kanye West; all including a wallet address. The promise was that a Bitcoin payment to the address would be paid back to users in double. The hackersmade approximately $121,000 from willful payments.</p><p>This cryptocurrency scam is the most easily avoided of the bunch. If you don’t know a user, don’t click any mysterious links. Typically, the scam is perpetuated by scammers on accounts that are brand new, have zero followers, and no profile picture. Even in the case of the famous Twitter hack that saw scams coming from verified accounts, it’s obvious that a promise to double one’s investment for free is illegitimate. Tom Robinson, co-founder of&nbsp;<b>Elliptic</b>,says of these scams, “what we often see with these type [sic] of exploits is that the exploit itself can be very sophisticated but they’re not very good at monetizing it.”</p><p>Some common sense and a keen sense of skepticism can go a long way.</p><p><b>The Bottom Line on Cryptocurrency Scams</b></p><p>This list isn’t all-encompassing; as cryptocurrencies change shape to fit consumers’ needs, so too will scams shapeshift to lure in new victims. Crypto is a booming industry, and a large part of that is because it is not regulated. Users can do whatever they want, which means some will use their privileges for malicious purposes.</p><p>Meme coins are going to keep cropping up, promising the success of&nbsp;<b>Dogecoin</b>(CCC:<b>DOGE-USD</b>). They’re not all illegitimate, but keep all of this information stored. You should be able to stay wary and skim the fakes from the pool. Likewise, fraudulent wallets and exchanges will continue popping up as long as legitimate ones keep hitting the market as “innovative new platforms in blockchain tech.”</p><p>Almost all crypto scams can be rooted out by simply taking a closer look. Scammers are sloppy — they make typos, they leave out details. If it walks like a scam, and it talks like a scam, it’s best to stay away, because it’s a scam.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Headed for the Moon? Make Sure You Avoid These 4 Big Cryptocurrency Scams</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeaded for the Moon? Make Sure You Avoid These 4 Big Cryptocurrency Scams\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/headed-for-the-moon-make-sure-you-avoid-these-4-big-cryptocurrency-scams/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cryptocurrencies are amazing. They allow us to send lightning-fast transactions overseas, develop applications in a decentralized way, encrypt information in a manner that is safe and effective, and —...</p>\n\n<a href=\"https://investorplace.com/headed-for-the-moon-make-sure-you-avoid-these-4-big-cryptocurrency-scams/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/headed-for-the-moon-make-sure-you-avoid-these-4-big-cryptocurrency-scams/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170226387","content_text":"Cryptocurrencies are amazing. They allow us to send lightning-fast transactions overseas, develop applications in a decentralized way, encrypt information in a manner that is safe and effective, and — most importantly — they give us an innovative new way to grow our wealth.Bitcoin(CCC:BTC-USD) blazed the trail, creating the first generation of crypto billionaires and blockchain entrepreneurs. In its wake, altcoins have been cropping up everywhere as potential gateways to gains. Although this crypto craze brings great opportunity, it also brings a wealth of cryptocurrency scams, like theElon Musk impersonators who’ve made off with millionsin coins.This new frontier of digital, decentralized finance can be a labyrinth for new investors. There are many bad actors who know that, and seek to take advantage of those who are just beginning to explore the complex world of cryptocurrencies.AtInvestorPlace, we want to ensure our readers are as educated as possible in order to tell the real from the fake. In the world of traditional investing, this means highlighting the risks that come with penny stocks and other volatile names. In the world of cryptocurrencies, it’s the same.And, just like with traditional pump-and-dump schemes and other stock scams, there are signs you can look for to avoid falling for fraud.Altcoin schemes are frustrating because they can take many forms.AARPsays it best, though: “For all cryptocurrency’s high-tech gloss, many of the related scams are just newfangled versions of classic frauds.”In the six months from October 2020 to May 2021, those Elon Musk impersonators have been making a killing. By just creating a Twitter account using Musk’s profile image and name, these scammers have convinced users to send over $2 million in Bitcoin to them. The scam, a play on the popular“Nigerian prince”email scheme, is shockingly lucrative. And, unfortunately, it’s only a drop in the bucket as far as crypto scams go.With this in mind, it’s a good idea to make yourself familiar with different crypto schemes to minimize the risk of falling victim to one. Let’s take a look at some of the most common crypto scams.Cryptocurrency Scams to Avoid: Fake ICOsA fake ICO, or initial coin offering, takes a similar shape to a pre-IPO scam. In it, a cryptocurrency will pop up. It will have a white paper and all the fixings, advertising a “groundbreaking” new blockchain tech oryield-farming modelthat is certain to bringhuge gains.These crypto scams usually also have great marketing. Victims are the type who are prone to speculative investing; they’ll bite, pouring money into an initial offering in order to get those “big gains.” Before you know it, they’re seeing no movement in their portfolio. Or, they’re getting a worthless token with absolutely no utility. The scammer rides off into the sunset with a full wallet.A famous example of a fake ICO is Pincoin. The development teamraised $660 million from investors, launched a different coin from the one advertised, and compensated the victims with loads of the worthless crypto before disappearing. The resulting protests outside their Ho Chi Minh City office were a fruitless effort; the seven developersemptied the commercial space and never came back.So how do you avoid these cryptocurrency scams? The key for spotting a fake ICO is in the details.This means you should pore over the white paper, which is the cornerstone document to a blockchain project. It contains all the details of how a crypto functions, how it is used, and the roadmap for the underlying company and team.The details of a white paper are where you will find the evidence of a scam. If it doesn’t have a white paper, that’s an immediate red flag. If there are typos, or if there is a lack of a clear vision or roadmap for the crypto, these are all signs of a cryptocurrency scam.Ponzi SchemesIf you’re at all familiar with investing, you are familiar with Ponzi schemes. The scam is one in which old investors are paid with the money of new investors, under the guise of receiving gains from their investment. It’s a scheme as old as — well, as old as Charles Ponzi, who originated the scam under the façade of selling discounted postage stamps.In the 100-plus years since, the scam has remained, but it’s become more sophisticated.With cryptos, a Ponzi scheme takes a similar form. Scammers offer huge gains through an “up and coming” new arbitrage model. Money is taken from the new investors, given to the old investors disguised as the gains, and the scammer pockets his share.The most notable Ponzi scheme in crypto isBitconnect, a high-yield investment program disguised as an open-source currency. Users could stake their coins for high daily interest, which was actually just money taken from newer investors. And the company made a huge profit; Bitconnectwas a top 20 cryptocurrencyin terms of market capitalization before its collapse.The U.S. Securities and Exchange Commissionkeeps a handy guideon spotting this particular crypto scheme. Investors should look out for the classic “high return, no risk” promise typical of a cryptocurrency scam. Overly complex strategies and returns that look uncannily consistent are also signs of fraud. Because of the nature of cryptos, overly consistent returns are unusual. Things ebb and flow on the market, so when returns are the same month after month, it suggests the gains are artificial.Cryptocurrency Scams to Avoid: Fraud WalletsA fraud wallet scam is closely related to the internet-age-old practice of phishing. But rather than sending out emails pretending to be a reputable company, fraud wallets typically wait for you to come to them.Fraud wallets can take the shape of a website or a mobile app, just like a real crypto wallet. Everything might seem totally legitimate: a shiny logo, high ratings, a sleek interface; heck, just the fact that a wallet app is on the Apple App Store could seem like reason enough to believe a wallet is real.Much like a lemon car, the fraud takes advantage of the adage “looks can be deceiving.” When one signs up for a fraudulent wallet, they do all the work for the scammer. They add in their information, link a card or two, and load crypto right into the scammers’ hands. Then, just as quickly as the scammers showed up, they vanish with the coins.Trezor’s doppelgänger app is a famous example of a fraud wallet scheme, evengetting coverage in theWashington Post. The app posed as Trezor, which is a reputable crypto wallet. However, the doppelgänger app was acting in bad faith and stripped customers’ coins. As a result, victims have lost nearly $1 million in cryptocurrency. The most disturbing part of it all is that the app was housed on Apple’s platform, a supposedly safe space to download applications. It proves that you can’t let your guard down.My advice here is to stick with the biggest wallet players. Look for wallets with blue checkmarks on their Twitter profiles. Go to websites through official links to be sure you’re on legitimate sites. Don’t necessarily trust an app just because it has hundreds of reviews on an app store; security firm ESET says to “only trust cryptocurrency-related and other finance apps if they are linked from the official website of the service.”Double and triple check that you’re looking through official channels when preparing to sign up for a wallet in-browser. If you go through as many channels as possible that evaluate content for fraud, the likelihood that you are using a crypto scam product decreases significantly.Social Media ScamsSocial media scams are not exclusive to cryptocurrency. They’ve been around as long as social media has existed, and while all seek different ends, many recent social media scams want your digital currency.Another variant of phishing, social media scams typically involve an account advertising big gains, a survey, or something similar, with a link. Clicking the link can lead to malware being installed on one’s device. Or, scammers can simply lure you into entering your information.In the crypto-sphere, these scams usually target Bitcoin holders, due simply to the coin’s high value and rapid growth. A famous scam occurred in 2020, when hackers gained access to a slew of different celebrities’ Twitter accounts. Tweets went out from Barack Obama, Elon Musk and Kanye West; all including a wallet address. The promise was that a Bitcoin payment to the address would be paid back to users in double. The hackersmade approximately $121,000 from willful payments.This cryptocurrency scam is the most easily avoided of the bunch. If you don’t know a user, don’t click any mysterious links. Typically, the scam is perpetuated by scammers on accounts that are brand new, have zero followers, and no profile picture. Even in the case of the famous Twitter hack that saw scams coming from verified accounts, it’s obvious that a promise to double one’s investment for free is illegitimate. Tom Robinson, co-founder of Elliptic,says of these scams, “what we often see with these type [sic] of exploits is that the exploit itself can be very sophisticated but they’re not very good at monetizing it.”Some common sense and a keen sense of skepticism can go a long way.The Bottom Line on Cryptocurrency ScamsThis list isn’t all-encompassing; as cryptocurrencies change shape to fit consumers’ needs, so too will scams shapeshift to lure in new victims. Crypto is a booming industry, and a large part of that is because it is not regulated. Users can do whatever they want, which means some will use their privileges for malicious purposes.Meme coins are going to keep cropping up, promising the success of Dogecoin(CCC:DOGE-USD). They’re not all illegitimate, but keep all of this information stored. You should be able to stay wary and skim the fakes from the pool. Likewise, fraudulent wallets and exchanges will continue popping up as long as legitimate ones keep hitting the market as “innovative new platforms in blockchain tech.”Almost all crypto scams can be rooted out by simply taking a closer look. Scammers are sloppy — they make typos, they leave out details. If it walks like a scam, and it talks like a scam, it’s best to stay away, because it’s a scam.","news_type":1},"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9029593286,"gmtCreate":1652796037445,"gmtModify":1676535162923,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Finally back to EV turn to go up and up&nbsp;","listText":"Finally back to EV turn to go up and up&nbsp;","text":"Finally back to EV turn to go up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9029593286","repostId":"1127355155","repostType":4,"repost":{"id":"1127355155","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652795130,"share":"https://ttm.financial/m/news/1127355155?lang=&edition=fundamental","pubTime":"2022-05-17 21:45","market":"us","language":"en","title":"EV Stocks Jumped in Morning Trading, with Rivian and Nio Rising Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127355155","media":"Tiger Newspress","summary":"EV stocks jumped in morning trading, with Rivian and Nio rising over 10%.","content":"<html><head></head><body><p>EV stocks jumped in morning trading, with Rivian and Nio rising over 10%.<img src=\"https://static.tigerbbs.com/556eba25f7a139d332295c18489271b2\" tg-width=\"317\" tg-height=\"476\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks Jumped in Morning Trading, with Rivian and Nio Rising Over 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks Jumped in Morning Trading, with Rivian and Nio Rising Over 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-17 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>EV stocks jumped in morning trading, with Rivian and Nio rising over 10%.<img src=\"https://static.tigerbbs.com/556eba25f7a139d332295c18489271b2\" tg-width=\"317\" tg-height=\"476\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","NIO":"蔚来"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127355155","content_text":"EV stocks jumped in morning trading, with Rivian and Nio rising over 10%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887392839,"gmtCreate":1631971257721,"gmtModify":1676530680286,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>&nbsp;Onwards to 300 dollars","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>&nbsp;Onwards to 300 dollars","text":"$Zoom(ZM)$ Onwards to 300 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887392839","isVote":1,"tweetType":1,"viewCount":112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814966617,"gmtCreate":1630745177339,"gmtModify":1676530389416,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LQDA\">$Liquidia Technologies Inc(LQDA)$</a>&nbsp;When can pass 3 dollars","listText":"<a href=\"https://laohu8.com/S/LQDA\">$Liquidia Technologies Inc(LQDA)$</a>&nbsp;When can pass 3 dollars","text":"$Liquidia Technologies Inc(LQDA)$ When can pass 3 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/814966617","isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813557173,"gmtCreate":1630218894792,"gmtModify":1676530246220,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813557173","repostId":"1184130616","repostType":4,"repost":{"id":"1184130616","kind":"news","pubTimestamp":1630111537,"share":"https://ttm.financial/m/news/1184130616?lang=&edition=fundamental","pubTime":"2021-08-28 08:45","market":"us","language":"en","title":"Wall Street Crime And Punishment: Bernard Ebbers And WorldCom's Seriously Wrong Numbers","url":"https://stock-news.laohu8.com/highlight/detail?id=1184130616","media":"Benzinga","summary":"Does crime pay?\nAmong the mightiest of the high-profile corporate executives that dominated the head","content":"<p><i>Does crime pay?</i></p>\n<p>Among the mightiest of the high-profile corporate executives that dominated the headlines in the 1990s and early 2000s,<b>Bernard Ebbers</b>physically stood out from his peers — the 6-foot-4 head of WorldCom was dubbed the “telecom cowboy” thanks to his sartorial preference for jeans, cowboy boots and a 10-gallon hat.</p>\n<p>Ebbers also stood out from his peers for tightly holding on to Luddite practices as the digital age dawned. He famously refused to communicate with his workforce via email. Even worse, he stood out thanks to a prickly personality that quickly seethed when confronted with unpleasant news. A 2002 profile in The Economist defined him as “parochial, stubborn, preoccupied with penny-pinching … a difficult man to work for.”</p>\n<p><b>But ultimately, Ebbers stood out for being at the center of what was (at the time) the largest accounting fraud in U.S. history, which was followed by the harshest prison sentence ever imposed on a corporate executive for financial crimes.</b></p>\n<p><b>A Man In Search Of Himself:</b>&nbsp;Bernard John Ebbers was born Aug. 27, 1941, in Edmonton, Alberta, the second of five children. His father John was a traveling salesman and his peripatetic profession brought the family down from Canada into California, where he jettisoned his sales work and became an auto mechanic. The family later relocated to Gallup, New Mexico, where Ebbers’ parents became teachers on the Navajo Nation Indian reservation.</p>\n<p>The Ebbers clan was back in Canada when Ebbers was a teenager and Bernie (as he was commonly known) came into adulthood unable to determine a course for his life. He&nbsp;attended Canada’s University of Alberta and Michigan’s Calvin College before accepting a basketball scholarship to Mississippi College. But he was the victim of a robbery prior to his senior year that left him seriously injured and switched his attention from playing to coaching the junior varsity team.</p>\n<p>Ebbers graduated in 1967 majoring in physical education and minoring in secondary education. He supported himself during his college years by taking on a variety of odd jobs including a bouncer and milk delivery driver. He married his college sweetheart,<b>Linda Pigott,</b>after graduating and landed work teaching science to middle-school students while coaching high school basketball.</p>\n<p>But Ebbers didn’t stay very long in the school system. When his wife received a job offer as a teacher in another Mississippi town, the couple relocated and he found work managing a garment factory warehouse. By 1974, he tired of working for others and responded to a newspaper advertisement seeking a buyer for a motel in Columbia, Mississippi.</p>\n<p>Ebbers’ approach to running a hospitality establishment sometimes bordered on the eccentric.&nbsp;He would distribute bathroom towels at the front desk and require guests to return them to avoid being charged for taking them. Nonetheless, he found a niche in hospitality management and by the early 1980s he owned and operated eight motels within Mississippi and Texas; he also picked up a car dealership that also proved profitable.</p>\n<p><b>Calling Out Around The World:</b>Ebbers might have remained in the Mississippi hospitality industry had it not been for the 1982 breakup of<b>AT&amp;T Inc.'s</b>&nbsp;T 0.41%monopoly on the U.S. telephone system. This created a seismic shift in the telecommunications world by enabling other companies to begin reselling long-distance telephone services.</p>\n<p>In 1983, Ebbers and three friends met at a diner in Hattiesburg, Mississippi, to consider the feasibility of pursuing this newly opened opportunity. Ebbers theorized that having control of his long-distance calling services could benefit his motel business. In the days before mobile phones, guests in lodging establishments in need of long-distance calling would either have to feed handfuls of quarters into payphones or make calls from their rooms, which usually came with extra fees.</p>\n<p>Ebbers and his pals decided to get into the telecommunications business with&nbsp;<b>Long Distance Discount Services,</b>&nbsp;which they established in 1985 with headquarters in Jackson, Mississippi, with Ebbers as CEO.</p>\n<p><b>Carl J. Aycock,</b>a Mississippi financial advisor who was among the early investors in LDDS, would later laugh at the unlikelihood of Ebbers running a telecom company.</p>\n<p>“The only experience Bernie had before operating a long-distance company was he used the phone,” Aycock quipped in a 1997 interview.</p>\n<p>Maybe Ebbers did not possess an encyclopedic knowledge of telecommunications technology, but the good fortune he enjoyed in the motel business transitioned to this unlikely setting. Within four years of its launch, LDDS was being publicly traded.</p>\n<p>Within 10 years of its opening, LDDS took on an almost Pac Man-style persona of gobbling up telecom firms in&nbsp;sight of the company, acquiring more than 60 different telecommunications company. By 1995, the company renamed itself LDDS WorldCom.</p>\n<p>Many of the company’s acquisitions were on the small side, and the company was never considered a major player in the telecom industry until its $720 million acquisition of&nbsp;<b>Advanced Telecommunications Corporation</b>&nbsp;in 1992.</p>\n<p>The unlikely acquisition came with Ebbers’ ability to outbid industry titans AT&amp;T and&nbsp;<b>Sprint Corporation,</b>both considerably larger players in this field.</p>\n<p>The one unfortunate development during this time was the end of Ebbers’ marriage in 1997. He remarried in 1999 to&nbsp;<b>Kristie Webb.</b></p>\n<p>In February 1998, Ebbers’ company launched its acquisition plans for&nbsp;<b>CompuServe</b>&nbsp;from&nbsp;<b>H&amp;R Block Inc</b>.</p>\n<p>This transaction was followed by an astonishing spin of assets: LDDS sold the CompuServe Information Service portion of its acquisition to<b>America Online,</b>while retaining the CompuServe Network Services portion of the business. AOL simultaneously sold LDDS WorldCom its networking division, Advanced Network Services.</p>\n<p>In September 1998, LDDS WorldCom sealed a $37 billion union with&nbsp;<b>MCI Communications,</b>which created the largest corporate merger in U.S. history. The combined entity became MCI WorldCom, and for Ebbers it seemed that the sky was the limit —&nbsp;except that Ebbers’ ability to soar in the corporate skies resulted in an Icarus-worthy predicament.</p>\n<p><b>A Little Out Of Touch:</b>One year after the CompuServe and MCI deals, Ebbers’ company boasted an 80,000-person workforce, a market capitalization of roughly $185 billion and its shares were trading at a peak of nearly $62.</p>\n<p>At the peak of the company’s success, Ebbers granted an interview to The New York Times aboard his 130-yacht, which he berthed in the resort town of Hilton Head, South Carolina. He claimed that the secret of his success was “not as complicated as people make it out to be,” adding that he surrounded himself with experts who advised him on which moves to make.</p>\n<p>“I’m not an engineer by training,” he said. “I’m not an accountant by training. I’m the coach. I’m not the point guard who shoots the ball.”</p>\n<p>But as the company grew larger, Ebbers penny-pinching behavior during his early motel management days became more extreme. WorldCom executives would later complain that Ebbers stopped providing free coffee within their offices and directed security guards fill the water coolers with tap water.</p>\n<p>And for the head of a telecommunications company, Ebbers was curiously distrustful of cutting-edge tech developments. He refused to communicate via email and would not carry a pager or a cell phone. He would explain his actions internally by repeating “That’s the way we did it at LDDS,” and in a 1997 Business Week interview about this behavior he claimed that “when you come to the table with a (physical education) degree like I do, you don't know a lot about the technical stuff.”</p>\n<p>While Ebbers’ arms-length distance from personal technology could have been attributed to a zany quirk, there was another problem that couldn’t be happily shrugged away. As the company expanded, operational problems began to permeate the multiple divisions. Ebbers would become impatient or worse when confronted with problems, to the point that he would angrily demand that he only wanted to be addressed with good news.</p>\n<p><b>In retrospect, Ebbers’ refusal to acknowledge that his company was growing too fast and too large proved to be a fatal flaw</b>, especially when the corporate culture began to manufacture good news in lieu of reporting problems. As a result, Ebbers’ XL-sized business empire was sustained by taking on massive amounts of debt and highly improper accounting.</p>\n<p><b>Detour Off The Cliff:</b>The first cracks in this corporate story began in October 1999 when MCI WorldCom —&nbsp;which had become the second-largest long-distance telephone company in the country —&nbsp;announced a $129 billion merger with Sprint, the third-largest telecom carrier. Within nine months of this announcement, the merger was canceled in the face of pressure from U.S. and European regulators who feared a telecom monopoly would be born from this union. MCI WorldCom walked away from the failure by renaming itself as WorldCom.</p>\n<p>With the rise of the new millennium came the fall of the dot-com industry, and almost any company that had a tech-related aspect found itself taking a financial tumble. When Ebbers’ company tried to cut corners and save money, it turned into an act of self-immolation.</p>\n<p>Worldcom’s network systems engineering division exhausted its annual capital expenditures budget by November 2000, with a&nbsp;senior manager ordering&nbsp;a halt to processing payments for network systems vendors and suppliers until the beginning of 2001.</p>\n<p>The company’s chief technical officer,<b>Fred Briggs,</b>then ordered all of the labor associated with the capital projects in the network systems division to be booked as an expense rather than a capital project —&nbsp;and his directive was shared with other divisions in the company.</p>\n<p>A WorldCom budget analyst named&nbsp;<b>Kim Amigh</b>in the company’s Richardson, Texas, office recognized the legal ramifications of intentionally mischaracterizing capital expenses and lodged a protest against the order. The directive was canceled and so was Amigh —&nbsp;three months after his action, Amigh was abruptly laid off from the company.</p>\n<p>But Vice President of Internal Audit&nbsp;<b>Cynthia Cooper</b>&nbsp;learned of Amigh’s findings and picked up his trail. Her department began combing through WorldCom’s accounts and found $2 billion that the company claimed in its public filings was spent on capital expenditures during the first three quarters of 2001 —&nbsp;except that the funds were never authorized for that purpose and were clearly operating costs moved into the capital expenditure accounting as a way to make WorldCom look more profitable.</p>\n<p>Cooper could not find anyone in the WorldCom leadership ranks to explain the $2 billion discrepancy. Most executives said it was a “prepaid capacity,” a meaningless term which they couldn’t define when pressed by Cooper.</p>\n<p>And Cooper was not alone in her suspicions. The U.S. Securities and Exchange Commission could not fathom how WorldCom continued to claim robust profits during the dot-com period while its competitors were operating at a loss, and it sent forth a “Request for Information” to learn the secret of its success.</p>\n<p>Adding to this chaos were Ebbers’ personal financial woes, which became exacerbated during to dot-com crisis by margin calls on his WorldCom shares, which were tanking as the economy plummeted into a recession.</p>\n<p>To alleviate his monetary pain, Ebbers borrowed $50 million from WorldCom in September 2000&nbsp;— and then borrowed again&nbsp;and again. By April 2002, Ebbers was $400 million in debt to WorldCom and the board of directors demanded his resignation, which he provided.</p>\n<p>In June 2002, WorldCom acknowledged its earnings reports contained $3.9 billion in accounting misstatements, with the figure&nbsp;later adjusted to $11 billion. In July 2002, the company declared bankruptcy and was delisted from public trading. Also during that month, Ebbers was called before the U.S. House of Representatives Committee on Financial Services to explain what happened. He pleaded the Fifth Amendment.</p>\n<p><b>Road’s End:</b>The efforts to bring Ebbers to trial got off to a weird start when the State of Oklahoma jumped the gun with a 15-count indictment, only to drop its charges in favor of federal prosecution.</p>\n<p>Ebbers was indicted in May 2004 on seven counts of filing false statements with securities regulators plus one count each of conspiracy and securities fraud. Ebbers agreed to testify on his behalf, which many observers later considered to be a major mistake because he came across as evasive and unconvincing when insisting WorldCom’s downfall was solely the fault of his subordinates and that he was ignorant about how his company worked.</p>\n<p>“I know what I don’t know,” Ebbers said during his trial. “To this day, I don’t know technology, and I don’t know finance or accounting.”</p>\n<p>Ebbers was found guilty on all counts and was sentenced to 25 years in prison, the longest sentence ever handed down in U.S. history for a financial fraud case against a corporate executive.</p>\n<p>He remained free on bail while fighting to overturn the verdict, but the conviction was upheld in the U.S. Court of Appeals for the Second Circuit in July 2006. Two months later, he drove himself in his luxury Mercedes-Benz to a low-security Louisiana prison to begin his sentence. Two years later, his wife Kristie successfully filed for divorce.</p>\n<p>After 13 years behind bars, Ebbers was granted a compassionate release on Dec. 21, 2019, due to a deteriorating state of health that included macular degeneration that left him legally blind, anemia, a weakened heart condition and the beginnings of dementia. He returned to his home in Brookhaven, Mississippi, and passed away on Feb. 2, 2020.</p>\n<p>In defining his rise to the top, Ebbers harkened back to his basketball days by insisting, “The coach's job is to get the best players and get them to play together.” But in explaining his fall from grace, Ebbers forgot that the core of coaching is accepting responsibility for the team’s performance and he blamed his “best players” for not being able to “play together” while absolving himself from their errors.</p>\n<p>Said Ebbers when confronted with his ultimate failure as the corporate equivalent of a coach: “I didn't have anything to apologize for.”</p>\n<p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Crime And Punishment: Bernard Ebbers And WorldCom's Seriously Wrong Numbers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Crime And Punishment: Bernard Ebbers And WorldCom's Seriously Wrong Numbers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-28 08:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/08/22680432/wall-street-crime-and-punishment-bernard-ebbers-and-worldcoms-seriously-wrong-numbers><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Does crime pay?\nAmong the mightiest of the high-profile corporate executives that dominated the headlines in the 1990s and early 2000s,Bernard Ebbersphysically stood out from his peers — the 6-foot-4 ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/08/22680432/wall-street-crime-and-punishment-bernard-ebbers-and-worldcoms-seriously-wrong-numbers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HRB":"H&R布洛克税务"},"source_url":"https://www.benzinga.com/news/21/08/22680432/wall-street-crime-and-punishment-bernard-ebbers-and-worldcoms-seriously-wrong-numbers","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184130616","content_text":"Does crime pay?\nAmong the mightiest of the high-profile corporate executives that dominated the headlines in the 1990s and early 2000s,Bernard Ebbersphysically stood out from his peers — the 6-foot-4 head of WorldCom was dubbed the “telecom cowboy” thanks to his sartorial preference for jeans, cowboy boots and a 10-gallon hat.\nEbbers also stood out from his peers for tightly holding on to Luddite practices as the digital age dawned. He famously refused to communicate with his workforce via email. Even worse, he stood out thanks to a prickly personality that quickly seethed when confronted with unpleasant news. A 2002 profile in The Economist defined him as “parochial, stubborn, preoccupied with penny-pinching … a difficult man to work for.”\nBut ultimately, Ebbers stood out for being at the center of what was (at the time) the largest accounting fraud in U.S. history, which was followed by the harshest prison sentence ever imposed on a corporate executive for financial crimes.\nA Man In Search Of Himself: Bernard John Ebbers was born Aug. 27, 1941, in Edmonton, Alberta, the second of five children. His father John was a traveling salesman and his peripatetic profession brought the family down from Canada into California, where he jettisoned his sales work and became an auto mechanic. The family later relocated to Gallup, New Mexico, where Ebbers’ parents became teachers on the Navajo Nation Indian reservation.\nThe Ebbers clan was back in Canada when Ebbers was a teenager and Bernie (as he was commonly known) came into adulthood unable to determine a course for his life. He attended Canada’s University of Alberta and Michigan’s Calvin College before accepting a basketball scholarship to Mississippi College. But he was the victim of a robbery prior to his senior year that left him seriously injured and switched his attention from playing to coaching the junior varsity team.\nEbbers graduated in 1967 majoring in physical education and minoring in secondary education. He supported himself during his college years by taking on a variety of odd jobs including a bouncer and milk delivery driver. He married his college sweetheart,Linda Pigott,after graduating and landed work teaching science to middle-school students while coaching high school basketball.\nBut Ebbers didn’t stay very long in the school system. When his wife received a job offer as a teacher in another Mississippi town, the couple relocated and he found work managing a garment factory warehouse. By 1974, he tired of working for others and responded to a newspaper advertisement seeking a buyer for a motel in Columbia, Mississippi.\nEbbers’ approach to running a hospitality establishment sometimes bordered on the eccentric. He would distribute bathroom towels at the front desk and require guests to return them to avoid being charged for taking them. Nonetheless, he found a niche in hospitality management and by the early 1980s he owned and operated eight motels within Mississippi and Texas; he also picked up a car dealership that also proved profitable.\nCalling Out Around The World:Ebbers might have remained in the Mississippi hospitality industry had it not been for the 1982 breakup ofAT&T Inc.'s T 0.41%monopoly on the U.S. telephone system. This created a seismic shift in the telecommunications world by enabling other companies to begin reselling long-distance telephone services.\nIn 1983, Ebbers and three friends met at a diner in Hattiesburg, Mississippi, to consider the feasibility of pursuing this newly opened opportunity. Ebbers theorized that having control of his long-distance calling services could benefit his motel business. In the days before mobile phones, guests in lodging establishments in need of long-distance calling would either have to feed handfuls of quarters into payphones or make calls from their rooms, which usually came with extra fees.\nEbbers and his pals decided to get into the telecommunications business with Long Distance Discount Services, which they established in 1985 with headquarters in Jackson, Mississippi, with Ebbers as CEO.\nCarl J. Aycock,a Mississippi financial advisor who was among the early investors in LDDS, would later laugh at the unlikelihood of Ebbers running a telecom company.\n“The only experience Bernie had before operating a long-distance company was he used the phone,” Aycock quipped in a 1997 interview.\nMaybe Ebbers did not possess an encyclopedic knowledge of telecommunications technology, but the good fortune he enjoyed in the motel business transitioned to this unlikely setting. Within four years of its launch, LDDS was being publicly traded.\nWithin 10 years of its opening, LDDS took on an almost Pac Man-style persona of gobbling up telecom firms in sight of the company, acquiring more than 60 different telecommunications company. By 1995, the company renamed itself LDDS WorldCom.\nMany of the company’s acquisitions were on the small side, and the company was never considered a major player in the telecom industry until its $720 million acquisition of Advanced Telecommunications Corporation in 1992.\nThe unlikely acquisition came with Ebbers’ ability to outbid industry titans AT&T and Sprint Corporation,both considerably larger players in this field.\nThe one unfortunate development during this time was the end of Ebbers’ marriage in 1997. He remarried in 1999 to Kristie Webb.\nIn February 1998, Ebbers’ company launched its acquisition plans for CompuServe from H&R Block Inc.\nThis transaction was followed by an astonishing spin of assets: LDDS sold the CompuServe Information Service portion of its acquisition toAmerica Online,while retaining the CompuServe Network Services portion of the business. AOL simultaneously sold LDDS WorldCom its networking division, Advanced Network Services.\nIn September 1998, LDDS WorldCom sealed a $37 billion union with MCI Communications,which created the largest corporate merger in U.S. history. The combined entity became MCI WorldCom, and for Ebbers it seemed that the sky was the limit — except that Ebbers’ ability to soar in the corporate skies resulted in an Icarus-worthy predicament.\nA Little Out Of Touch:One year after the CompuServe and MCI deals, Ebbers’ company boasted an 80,000-person workforce, a market capitalization of roughly $185 billion and its shares were trading at a peak of nearly $62.\nAt the peak of the company’s success, Ebbers granted an interview to The New York Times aboard his 130-yacht, which he berthed in the resort town of Hilton Head, South Carolina. He claimed that the secret of his success was “not as complicated as people make it out to be,” adding that he surrounded himself with experts who advised him on which moves to make.\n“I’m not an engineer by training,” he said. “I’m not an accountant by training. I’m the coach. I’m not the point guard who shoots the ball.”\nBut as the company grew larger, Ebbers penny-pinching behavior during his early motel management days became more extreme. WorldCom executives would later complain that Ebbers stopped providing free coffee within their offices and directed security guards fill the water coolers with tap water.\nAnd for the head of a telecommunications company, Ebbers was curiously distrustful of cutting-edge tech developments. He refused to communicate via email and would not carry a pager or a cell phone. He would explain his actions internally by repeating “That’s the way we did it at LDDS,” and in a 1997 Business Week interview about this behavior he claimed that “when you come to the table with a (physical education) degree like I do, you don't know a lot about the technical stuff.”\nWhile Ebbers’ arms-length distance from personal technology could have been attributed to a zany quirk, there was another problem that couldn’t be happily shrugged away. As the company expanded, operational problems began to permeate the multiple divisions. Ebbers would become impatient or worse when confronted with problems, to the point that he would angrily demand that he only wanted to be addressed with good news.\nIn retrospect, Ebbers’ refusal to acknowledge that his company was growing too fast and too large proved to be a fatal flaw, especially when the corporate culture began to manufacture good news in lieu of reporting problems. As a result, Ebbers’ XL-sized business empire was sustained by taking on massive amounts of debt and highly improper accounting.\nDetour Off The Cliff:The first cracks in this corporate story began in October 1999 when MCI WorldCom — which had become the second-largest long-distance telephone company in the country — announced a $129 billion merger with Sprint, the third-largest telecom carrier. Within nine months of this announcement, the merger was canceled in the face of pressure from U.S. and European regulators who feared a telecom monopoly would be born from this union. MCI WorldCom walked away from the failure by renaming itself as WorldCom.\nWith the rise of the new millennium came the fall of the dot-com industry, and almost any company that had a tech-related aspect found itself taking a financial tumble. When Ebbers’ company tried to cut corners and save money, it turned into an act of self-immolation.\nWorldcom’s network systems engineering division exhausted its annual capital expenditures budget by November 2000, with a senior manager ordering a halt to processing payments for network systems vendors and suppliers until the beginning of 2001.\nThe company’s chief technical officer,Fred Briggs,then ordered all of the labor associated with the capital projects in the network systems division to be booked as an expense rather than a capital project — and his directive was shared with other divisions in the company.\nA WorldCom budget analyst named Kim Amighin the company’s Richardson, Texas, office recognized the legal ramifications of intentionally mischaracterizing capital expenses and lodged a protest against the order. The directive was canceled and so was Amigh — three months after his action, Amigh was abruptly laid off from the company.\nBut Vice President of Internal Audit Cynthia Cooper learned of Amigh’s findings and picked up his trail. Her department began combing through WorldCom’s accounts and found $2 billion that the company claimed in its public filings was spent on capital expenditures during the first three quarters of 2001 — except that the funds were never authorized for that purpose and were clearly operating costs moved into the capital expenditure accounting as a way to make WorldCom look more profitable.\nCooper could not find anyone in the WorldCom leadership ranks to explain the $2 billion discrepancy. Most executives said it was a “prepaid capacity,” a meaningless term which they couldn’t define when pressed by Cooper.\nAnd Cooper was not alone in her suspicions. The U.S. Securities and Exchange Commission could not fathom how WorldCom continued to claim robust profits during the dot-com period while its competitors were operating at a loss, and it sent forth a “Request for Information” to learn the secret of its success.\nAdding to this chaos were Ebbers’ personal financial woes, which became exacerbated during to dot-com crisis by margin calls on his WorldCom shares, which were tanking as the economy plummeted into a recession.\nTo alleviate his monetary pain, Ebbers borrowed $50 million from WorldCom in September 2000 — and then borrowed again and again. By April 2002, Ebbers was $400 million in debt to WorldCom and the board of directors demanded his resignation, which he provided.\nIn June 2002, WorldCom acknowledged its earnings reports contained $3.9 billion in accounting misstatements, with the figure later adjusted to $11 billion. In July 2002, the company declared bankruptcy and was delisted from public trading. Also during that month, Ebbers was called before the U.S. House of Representatives Committee on Financial Services to explain what happened. He pleaded the Fifth Amendment.\nRoad’s End:The efforts to bring Ebbers to trial got off to a weird start when the State of Oklahoma jumped the gun with a 15-count indictment, only to drop its charges in favor of federal prosecution.\nEbbers was indicted in May 2004 on seven counts of filing false statements with securities regulators plus one count each of conspiracy and securities fraud. Ebbers agreed to testify on his behalf, which many observers later considered to be a major mistake because he came across as evasive and unconvincing when insisting WorldCom’s downfall was solely the fault of his subordinates and that he was ignorant about how his company worked.\n“I know what I don’t know,” Ebbers said during his trial. “To this day, I don’t know technology, and I don’t know finance or accounting.”\nEbbers was found guilty on all counts and was sentenced to 25 years in prison, the longest sentence ever handed down in U.S. history for a financial fraud case against a corporate executive.\nHe remained free on bail while fighting to overturn the verdict, but the conviction was upheld in the U.S. Court of Appeals for the Second Circuit in July 2006. Two months later, he drove himself in his luxury Mercedes-Benz to a low-security Louisiana prison to begin his sentence. Two years later, his wife Kristie successfully filed for divorce.\nAfter 13 years behind bars, Ebbers was granted a compassionate release on Dec. 21, 2019, due to a deteriorating state of health that included macular degeneration that left him legally blind, anemia, a weakened heart condition and the beginnings of dementia. He returned to his home in Brookhaven, Mississippi, and passed away on Feb. 2, 2020.\nIn defining his rise to the top, Ebbers harkened back to his basketball days by insisting, “The coach's job is to get the best players and get them to play together.” But in explaining his fall from grace, Ebbers forgot that the core of coaching is accepting responsibility for the team’s performance and he blamed his “best players” for not being able to “play together” while absolving himself from their errors.\nSaid Ebbers when confronted with his ultimate failure as the corporate equivalent of a coach: “I didn't have anything to apologize for.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061499584,"gmtCreate":1651659895809,"gmtModify":1676534943682,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061499584","repostId":"2232029455","repostType":4,"repost":{"id":"2232029455","kind":"news","pubTimestamp":1651659196,"share":"https://ttm.financial/m/news/2232029455?lang=&edition=fundamental","pubTime":"2022-05-04 18:13","market":"us","language":"en","title":"Barrick Gold Non-GAAP EPS of $0.26 Beats by $0.02, Revenue of $2.85B Beats by $100M","url":"https://stock-news.laohu8.com/highlight/detail?id=2232029455","media":"seekingalpha","summary":"Barrick Gold (NYSE:GOLD): Q1  Non-GAAP EPS of $0.26  beats by $0.02. Barrick Gold shares rose 0.4% i","content":"<html><head></head><body><p>Barrick Gold (NYSE:GOLD): Q1  Non-GAAP EPS of $0.26  beats by $0.02. Barrick Gold shares rose 0.4% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/5d613e9c817c1254fbb858e7ca67af7d\" tg-width=\"848\" tg-height=\"631\" width=\"100%\" height=\"auto\"/></p><p>Revenue of $2.85B (-3.7% Y/Y)  beats by $100M.</p><p>Operating cash flow of $1,004 million and free cash flow1 of $393 million for the quarter</p><p>Net cash of $743 million results in a $0.20 per share dividend for Q1 2022, inclusive of a $0.10 per share performance dividend.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barrick Gold Non-GAAP EPS of $0.26 Beats by $0.02, Revenue of $2.85B Beats by $100M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarrick Gold Non-GAAP EPS of $0.26 Beats by $0.02, Revenue of $2.85B Beats by $100M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-04 18:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3831781-barrick-gold-non-gaap-eps-of-0_26-beats-0_02-revenue-of-2_85b-beats-100m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barrick Gold (NYSE:GOLD): Q1  Non-GAAP EPS of $0.26  beats by $0.02. Barrick Gold shares rose 0.4% in premarket trading.Revenue of $2.85B (-3.7% Y/Y)  beats by $100M.Operating cash flow of $1,004 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3831781-barrick-gold-non-gaap-eps-of-0_26-beats-0_02-revenue-of-2_85b-beats-100m\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOLD":"巴里克黄金"},"source_url":"https://seekingalpha.com/news/3831781-barrick-gold-non-gaap-eps-of-0_26-beats-0_02-revenue-of-2_85b-beats-100m","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232029455","content_text":"Barrick Gold (NYSE:GOLD): Q1  Non-GAAP EPS of $0.26  beats by $0.02. Barrick Gold shares rose 0.4% in premarket trading.Revenue of $2.85B (-3.7% Y/Y)  beats by $100M.Operating cash flow of $1,004 million and free cash flow1 of $393 million for the quarterNet cash of $743 million results in a $0.20 per share dividend for Q1 2022, inclusive of a $0.10 per share performance dividend.","news_type":1},"isVote":1,"tweetType":1,"viewCount":482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813057790,"gmtCreate":1630116226110,"gmtModify":1676530228429,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;Go to 20 dollars please&nbsp;","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;Go to 20 dollars please&nbsp;","text":"$BlackBerry(BB)$ Go to 20 dollars please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813057790","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}